Beta Drugs Limited recently held their Q4 FY26 earnings call, overseen by Phillip Capital PCG, according to the operator's announcement.

Beta Drugs reports a significant 282.5% jump in Q4 net profit for FY26, with earnings per share (EPS) reaching ₹5.26. This impressive growth resulted in the stock delivering 24% returns over the past year and closing at ₹1,416.8.

Beta Drugs has successfully met regulatory milestones in both Azerbaijan and the Philippines, signaling progress. The company is now focusing on obtaining GMP approval in the immediate future.